|
US2019328755A1
|
|
Methods of treating complex regional pain syndrome (crps) or symptoms comprising administration of neridronic acid
|
|
TW201832765A
|
|
Composition for intravesical administration for treating bladder pain
|
|
KR20190057349A
|
|
Stable formulation for parenteral administration of tapentadol
|
|
TW201815762A
|
|
6-membered cyclic amines or lactames substituted with urea and phenyl
|
|
CA3032598A1
|
|
Tamper resistant dosage form comprising an anionic polysaccharide
|
|
US2018000847A1
|
|
Crystallization method and bioavailability
|
|
WO2017195031A1
|
|
Novel crystalline forms
|
|
CN108779075A
|
|
3- (carboxymethyl group) -8- amino -2- oxos -1,3- aza-spiro-[4.5]-decane derivative
|
|
KR20170139158A
|
|
Immediate release and solvent extraction inhibition modulated dosage form
|
|
CA2955071A1
|
|
Substituted azaspiro(4.5)decane derivatives
|
|
AU2015203219A1
|
|
Tapentadol for use in the treatment of irritable bowel syndrome
|
|
CA2949422A1
|
|
Multiparticles safeguarded against ethanolic dose-dumping
|
|
AU2015258472A1
|
|
Device and formulation for topical treatment of pain affecting the vulvar area of the female human genital organ
|
|
CN106572980A
|
|
Tamper resistant immediate release capsule formulation comprising tapentadol
|
|
AU2014365741A1
|
|
Fluoromethyl-substituted pyrrole carboxamides as CaV2.2 calcium channel blockers
|
|
CN105934241A
|
|
Preparation of a powdery pharmaceutical composition by means of cryo-milling
|
|
CA2913209A1
|
|
Tamper resistant dosage form with bimodal release profile
|
|
TW201512189A
|
|
Novel substituted condensed pyrimidine compounds
|
|
AU2014211756A1
|
|
Novel substituted condensed pyrimidine compounds
|
|
CN104994851A
|
|
Pyrazolyl-based carboxamides i as crac channel inhibitors
|
